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Objectives This study sought to describe the first human series of percutaneous tricuspid valve replacements in patients
with congenital or acquired tricuspid valve (TV) disease.
Background Percutaneous transcatheter heart valve replacement of the ventriculoarterial (aortic, pulmonary) valves is estab-
lished. Although there are isolated reports of transcatheter atrioventricular heart valve replacement (hybrid and
percutaneous), this procedure has been less frequently described; we are aware of no series describing this pro-
cedure for TV disease.
Methods We approached institutions with significant experience with the Melody percutaneous pulmonary valve
(Medtronic, Inc., Minneapolis, Minnesota) to collect data where this valve had been implanted in the tricuspid
position. Clinical and procedural data were gathered for 15 patients. Indications for intervention included severe
hemodynamic compromise and perceived high surgical risk; all had prior TV surgery and significant stenosis
and/or regurgitation of a bioprosthetic TV or a right atrium–to–right ventricle conduit.
Results Procedural success was achieved in all 15 patients. In patients with predominantly stenosis, mean tricuspid gra-
dient was reduced from 12.9 to 3.9 mm Hg (p  0.01). In all patients, tricuspid regurgitation was reduced to
mild or none. New York Heart Association functional class improved in 12 patients. The only major procedural
complication was of third-degree heart block requiring pacemaker insertion in 1 patient. One patient developed
endocarditis 2 months after implant, and 1 patient with pre-procedural multiorgan failure did not improve and
died 20 days after the procedure. The remaining patients have well-functioning Melody valves in the TV position
a median of 4 months after implantation.
Conclusions In selected cases, patients with prior TV surgery may be candidates for percutaneous TV replacement. (J Am
Coll Cardiol 2011;58:117–22) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.044Primary tricuspid valve (TV) disease is a rare entity, the
etiology of which can be either congenital (e.g., Ebstein’s
anomaly or primary TV dysplasia) or acquired (e.g., rheu-
matic, endocarditis, or carcinoid disease). Tricuspid valve
replacement (TVR), therefore, is not a common operation
From the *Royal Prince Alfred Hospital, Sydney, Australia; †Children’s Hospital at
Westmead, Sydney, Australia; ‡Hopital Necker Enfants Malades, Paris, France;
§Nationwide Children’s Hospital, Columbus, Ohio; German Heart Centre, Mu-
nich, Germany; ¶German Heart Institute Berlin, Berlin Germany; #University Clinic
Giessen, Giessen, Germany; **Children’s Hospital Boston, Boston, Massachusetts;
††Miami Children’s Hospital, Miami, Florida; and the ‡‡Lankenau Institute for
Medical Research, Wynnewood, Pennsylvania. Drs. Roberts, Cheatham, Eicken, Ewert,
McElhinney, Berger, Hess, and Zahn are proctors and/or consultants for Medtronic, Inc. The
other authors have reported that they have no relationships to disclose.
Manuscript received December 6, 2010; accepted January 4, 2011.and, in most series, is associated with high post-operative
mortality, despite advances in perioperative care (1–4).
See page 123
There continues to be debate in the surgical literature
regarding whether bioprosthetic or mechanical valves are
preferable in the TV position, with many centers preferring
bioprosthetic valves due to the high failure rates and the
anticoagulation and thrombotic complications associated
with mechanical valves in this setting (3,5,6). Although
bioprosthetic valves appear to have improved performance
early after surgery, these valves will inevitably experience
wear and degeneration, requiring a second implant.
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first successful percutaneous
valve implantation was described
(7), and in the past decade, a
large amount of experience has
been gained with transcatheter
valve replacement for the aortic
and pulmonary valves (8,9). In
contrast, there has been very lim-
ited experience regarding the fea-
sibility of percutaneous valve im-
plantation in the tricuspid position.
This report describes the combined experience of 8
centers with implantation of the Melody transcatheter
pulmonary valve (Medtronic, Inc., Minneapolis, Minne-
sota) both in the orthotopic tricuspid position and right
atrium (RA) to right ventricle (RV) conduit.
Methods
Case finding. A data sheet was circulated to all centers
known to have requested the use of the Melody valve on a
“special request” basis with institutional review board approval
as applicable for use in the TV position. For each case
identified, the following data were collected: age, weight, sex,
diagnosis, previous surgical procedures, indication for TV
surgery, number of previous TV procedures, details of surgi-
cally placed bioprosthesis, pre- and post-echocardiographic
data, procedure date, percutaneous route, size of delivery
system used, procedure and screening times, complications,
medication pre- and post-procedure, and duration of
follow-up. Statistics were carried out using SPSS software
(version 17.0, IBM, Armonk, New York). p values for
gradient reduction were calculated using the paired t test.
Procedural details. Prior to each procedure, a careful
evaluation of the inner dimension of the tricuspid biopros-
thesis or RA-RV conduit was made to assess for the
Abbreviations
and Acronyms
NYHA  New York Heart
Association
RA  right atrium
RV  right ventricle
TV  tricuspid valve
TVR  tricuspid valve
replacement
Patient Demographics, Diagnoses, and PreviousTable 1 Patient Demographics, Diagnoses,
Case # Age, yrs Sex Weight, kg
1 8 F 29
2 9 M 29.8
3 25 M 68
4 27 M 43
5 29 M 83
6 30 F 110
7 31 F 52
8 31 M 75
9 32 F 67
10 39 F 71
11 42 M 97
12 45 F 56
13 51 F 100
14 57 F 87
15 64 F 55RA  right atrium; RV  right ventricle; TA  tricuspid atresia; TS  tricusp
VSD  ventricular septal defect.presence of a suitable anchor point and to ensure that
adequate expansion of the Melody valve would be achiev-
able. Standard venous vascular access techniques were used
for right heart catheterization. All procedures were per-
formed under general anesthesia using fluoroscopy with or
without echocardiographic guidance.
Results
A total of 15 patients were identified from 8 centers. The
primary indication for the procedure was predominantly
stenosis in 10 (mean gradient 5 mm Hg) and predomi-
nantly regurgitation in 5 (moderate to severe tricuspid
regurgitation and mean gradient 5 mm Hg or less). As
expected, a mixed pattern of both stenosis and regurgitation
was frequently present. Demographic data and diagnoses are
shown in Table 1 with procedural details in Table 2. Mean
nd median ages were 33 and 31.5 years (range 8 to 64
ears) and mean and median weight 69 kg (range 29 to 110
g). All patients were symptomatic with pre-procedure New
ork Heart Association (NYHA) functional class graded as
V in 1 patient, class III in 10 patients, and class II in 3
atients (Fig. 1). The ventilated patient with multisystem
rgan failure was excluded from the NYHA functional
lassification. Five procedures involved Melody valve im-
lantation into a dysfunctional RA-RV conduit in the
etting of a functionally single-ventricle Fontan palliation,
nd 10 involved implantation into a dysfunctional biopros-
hetic valve located in the orthotopic TV position (Table 2).
alve delivery and deployment were performed via the
emoral vein in 11 and the internal jugular vein in 4 patients.
re-dilation or low-pressure balloon sizing was utilized in 4
atients prior to valve delivery. A 22-mm Ensemble delivery
ystem (Medtronic Inc.) was used in all patients except 1,
here a 24-mm BIB balloon (Numed, Hopington, New
ork) was used due to the large diameter of the previously
roceduresrevious TV Procedures
rimary Diagnosis Previous TV Procedures
osure then TVR 1 TVR
’s 4 TVR
hypoplastic RV 1 TVR
gy of Fallot 1 repair, 1TVR
t RA-RV conduit Fontan 2 conduits, 3 conduit stents
fective endocarditis 1 TVR
outlet right ventricle 2 TVR
t RA-RV conduit Fontan 1
t RA-RV conduit Fontan 2 conduits
fective endocarditis 1 TVR
t RA-RV conduit Fontan 2 conduits
t RA-RV conduit Fontan 2 conduits
fective endocarditis 1 TVR
atic heart disease 1 TVR
atic heart disease 1 TVRTV Pand P
P
VSD cl
Ebstein
TS and
Tetralo
TA pos
TVR in
Double
TA pos
TA pos
TVR in
TA pos
TA pos
TVR in
Rheum
Rheumid stenosis; TV  tricuspid valve; TVR  tricuspid valve replacement;
interna
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quate apposition of the Melody valve. Post-implantation
dilation of the Melody valve using higher pressure valvulo-
plasty balloons was performed in 7 patients. Average pro-
cedure and screening times were 120  64 min (range 54 to
251 min) and 29  18 min (range 8.3 to 74 min),
respectively. In 1 patient (Case #15), a Melody valve was
implanted in both the tricuspid and pulmonary valve posi-
tions at the same procedure. Figures 2 to 4 show pre- and
post-echocardiographic and fluoroscopic images, and Figure
5 shows balloon interrogation of a bioprosthesis.
In those patients being treated primarily for stenosis, the
median valve gradient was reduced from 12.5 to 3.5 mm Hg
(mean 12.9 to 3.9 mm Hg) (p  0.01). The median
post-procedure TV gradient for all patients was 2 mm Hg
(mean 2.9 mm Hg, range 0 to 7 mm Hg) (p  0.01). No
Procedural DetailsTable 2 Procedural Details
Case # Approach Bioprosthesis Type
Gradient
Pre Post
1 Femoral 23 mm CE 5 2
2 LIJ 23 mm MM 8 5
3 Femoral CE No 14 conduit 17 7
4 Femoral 27 mm MM 10 3
5 Femoral Patched Dacron tube 4 1
6 RIJ 27 mm MM 13 3
7 Femoral 25 mm MM 3 2
8 Femoral 26 mm Homograft 12 2
9 Femoral 22 mm CE 12 2
10 RIJ 27 mm CE 14 5
11 Femoral 30 mm Hancock 5 0
12 Femoral 31 mm homograft — 0
13 RIJ 31 mm CE 14 6
14 Femoral Sorin Bicarbon 33 20 4
15 Femoral 29 mm CE 9 2
Mean Doppler gradients are in mm Hg.
CE  Carpentier Edwards; LIJ  left internal jugular vein; MM  Medtronic Mosaic; RIJ  right
Figure 1 Before and After NYHA Functional Class
for the 14 Surviving Patients
An improvement in functional class was noted in 12 of 14 surviving patients.
NYHA  New York Heart Association.patient had more than mild tricuspid regurgitation at the
completion of the procedure, with 10 having no regurgitation
as judged by echocardiography. One patient, in whom the
valve was implanted with a 24-mm balloon, developed early
progressive (from mild to moderate) tricuspid regurgitation.
This patient, who was comatose with multisystem organ failure
prior to Melody implantation, experienced initial improvement
with a reduction in mean valve gradient from 14 to 6 mm Hg
associated with a transient improvement in mental state, but
ultimately died 2 days after surgical removal and replacement
of the valve, 20 days after the initial implant.
Other complications included 1 case of third-degree heart
block necessitating pacemaker implantation and 1 case of
Melody valve endocarditis requiring valve removal 2 months
post-implant (Fig. 6).
At latest follow-up (mean 9 months, and median of 4
months, range 0 to 38 months), 14 of 15 patients who
underwent the procedure are alive and well with 13 of 14
retaining the Melody valve in the TV position. NYHA
functional class improved acutely in all but 2 of the
surviving patients (Fig. 1).
Discussion
Major advances in the surgical management of congenital
and acquired right-sided valvular heart disease have allowed
the survival of increasing numbers of affected patients with
congenital or acquired disease. The right side of the heart
provides its own special set of anatomical and functional
considerations, often necessitating the use of a bioprosthetic
valve or valved conduit, all of which have a variable but
limited longevity.
A considerable body of literature supports the use of the
Melody valve in a stenotic and/or regurgitant RV to
Tricuspid Regurgitation
Screening Time (min) ComplicationsPre Post
Severe None 8.6 None
Severe Mild 25 Endocarditis
None None 33 None
Moderate None 10 None
Severe None 37 None
Mild Mild 10.6 None
Severe Mild 32.8 None
Mild None 57 None
Moderate None 22 None
Moderate Mild 74 None
Moderate None 21 None
Severe None 8.3 None
Mild Mild 35 Died
None None 15 Heart block
Mild None 30 None
l jugular vein.pulmonary artery conduit with particular morphologic fea-
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valve replacements have been performed worldwide (9).
Following development of transcatheter heart valve replace-
ment in the ventriculoarterial valve position for high-risk
surgical patients, the natural extension was to look for
options for nonsurgical treatment of the stenotic and/or
regurgitant RA-RV connection in patients considered high
surgical risk. Transcatheter heart valve use has been reported
in a prosthetic RA to RV conduit (Bjork-type connection in
a complex univentricular-type heart) (10), and preliminary
animal work has reported percutaneous TVR in the native
valve annulus (11). Webb et al. (12) recently reported
implantation of an Edwards Sapien valve (Edwards Life-
Figure 2 Before and After 2D and Color Doppler Transthoracic
(Top) The severe regurgitation of the bioprosthesis in the orthotopic TV position (t
image shows a narrow stenotic jet of color flow that is relieved after Melody valve
ventricle.
Figure 3 3 Lateral Angiograms Taken
Before and After Melody Deployment
The left-hand image shows significant regurgitation of contrast from the right ven-
tricle back into the right atrium. The right-hand image is after Melody valve deploy-
ment and shows a competent RA-RV connection. Abbreviations as in Figure 2.sciences, Irvine, California) in a patient with a TV biopros-
thesis using a hybrid approach with transcatheter delivery of
the valve through thoracotomy access. There is a case report
of a percutaneous valve placed inside a bioprosthetic valve
for tricuspid stenosis (13); this patient is included in the
current series (Case #6 in Tables 1 and 2).
We now report a series of 15 percutaneous TVRs using a
bioprosthetic valve placed inside a previously implanted
bioprosthetic valve or valved conduit, with important he-
modynamic compromise. This series shows that percutane-
ous TVR is achievable with a high procedural success rate,
when undertaken by groups experienced with transcatheter
cardiograms
t) is abolished after Melody valve insertion (top right). (Bottom) The bottom left
ment (bottom right). 2D  2-dimensional; RA  right atrium; RV  right
Figure 4 Angiograms of the RA-RV Conduit
Before and After Melody Valve Deployment
The left-hand image shows stenosis within the bioprosthetic valve. The right-
hand image is taken after Melody valve insertion and shows that stenosis has
been relieved. There is no significant regurgitation back into the RA. Abbrevia-
tions as in Figure 2.Echo
op lef
deploy
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This procedure may potentially reduce the total number of
open cardiac bypass surgical procedures that a patient may
have to undergo during their lifetime and does not appear to
preclude or jeopardize the future use of a surgical approach
should it be required. The advent of newer, larger devices
that could be expanded beyond the current 22-mm upper
limit of the Melody valve may further enhance the oppor-
tunities for percutaneous TV treatment.
There were some important complications observed. Prox-
imity to the conduction system means that there is a risk of
heart block, and this was observed in 1 case, requiring pace-
maker insertion. There are some data indicating a risk of
medium-term endocarditis with the Melody valve (14), and
this was indeed observed in 1 of our patients. One patient died,
although we note that this patient had been critically ill prior to
the procedure and died soon after surgical replacement of the
TV, highlighting the risk of surgery in this group of patients.
Melody valve competence has been tested and recommended
up to a diameter of 22 mm. Using a 24-mm BIB to deliver the
Melody may explain why this patient had developed moderate
tricuspid regurgitation post-procedure.
There are limitations to this study. Data were collected
retrospectively from centers experienced with percutaneous
pulmonary valve implantation, and thus the results pre-
sented may not be generally applicable. Furthermore, re-
porting as well as selection bias may be possible, although
the participating centers did enter all of their relevant
patients in this series. On the other hand, the procedure was
generally attempted only in very high-risk patients, which
may have influenced adversely the number of complications
seen. Finally, this is an early and preliminary report of a
novel procedure (median follow-up was only 4 months,
range: 0 to 38 monts), which was done “off label” for
Figure 5 Balloon Interrogation of the
Bioprosthesis Before Melody Valve Insertion
A contrast-filled balloon inflated within the bioprosthetic valve was useful in
identifying the site and degree of maximum stenosis as well as allowing for
pre-dilation.humanitarian reasons; longer-term follow-up is clearly re-
quired to better understand the results beyond the short
term, including valve function in the tricuspid position in
relation to RV loading, RV systolic and end-diastolic
pressure, ejection fraction, potential for stent fracture, ar-
rhythmia, and exercise capacity.
Conclusions
In selected cases, with a suitable anchor point in a surgically
placed but now dysfunctional bioprosthetic connection be-
tween the RA and RV, successful relief of stenosis and/or
regurgitation can be achieved via the percutaneous place-
ment of a stented bioprosthetic valve delivered via the
percutaneous transvenous route.
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